GSK plc
GSK- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001131399
No open-market purchases or sales by GSK plc insiders were filed in the last 90 days; 1,048 institutions reported holding it in 13F filings for Q2 2026, worth $18.2B in total; no superinvestor holds it.
Other share classesGLAXF
Q1 2024 vs. Q4 2023
How the institutions holding GSK plc changed between Q4 2023 and Q1 2024.
All holders in Q1 2024All holders in Q4 2023
| Measure | Q4 2023 | Of which not filed for Q1 2024 | Q1 2024 | Change |
|---|---|---|---|---|
| Holders | 897 | 8 | 911 | +22 |
| Shares | 291.2M | 52.8K | 311.1M | +19.9M (+6.8%) |
| Value | $10.8B | $1.96M | $13.3B | +$2.52B (+23.4%) |
8 institutions that held it in Q4 2023 haven't filed for Q1 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (101)
Institutions that held GSK plc at the end of Q1 2024 but not at the end of Q4 2023.
Showing the largest 100 of 101 by value.
Sold out (79)
Institutions that held GSK plc at the end of Q4 2023 and filed for Q1 2024 without it.
Not filed for Q1 2024 yet (8)
Institutions that held GSK plc at the end of Q4 2023 and haven't filed a 13F for Q1 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2023 | Value, Q4 2023 |
|---|---|---|
| Hudson Portfolio Management LLC | 21,636 | $801.8K |
| Traverso Chambers Private Wealth Management, LLC | 16,681 | $618.2K |
| Alan B. Lancz & Associates, Inc. | 11,060 | $409.9K |
| Coppell Advisory Solutions LLC | 1,855 | $68.7K |
| Bartlett & Co. LLC | 1,319 | $49.0K |
| Hobbs Group Advisors, LLC | 160 | $5.93K |
| Provence Wealth Management Group | 117 | $4.34K |
| Live Oak Investment Partners | – | $3.19K |